February 3, 2022
Mitsubishi Tanabe Pharma said on February 2 that its schizophrenia treatment cariprazine has received approval from Singaporean regulatory authorities for an additional indication of bipolar disorder. The company’s Singaporean subsidiary earned the green light on January 25. Cariprazine, known with...read more